DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Acular PF (Ketorolac Tromethamine Ophthalmic) - Summary

 
 



ACULAR PF SUMMARY

ACULAR® PF
(ketorolac tromethamine ophthalmic solution) 0.5%
Preservative-Free
Sterile

ACULAR® PF (ketorolac tromethamine ophthalmic solution) Preservative-Free is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use.

ACULAR® PF ophthalmic solution is indicated for the reduction of ocular pain and photophobia following incisional refractive surgery.


See all Acular PF indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Acular PF (Ketorolac Tromethamine Ophthalmic)

Pain care and management for older Americans
Source: Caregivers / Homecare News From Medical News Today [2014.11.22]
The first issue of a new publication series from The Gerontological Society of America (GSA) called From Policy to Practice explores pain as a public health problem and takes a look at how various...

Abuse-Resistant Prescription Painkiller Approved
Source: MedicineNet Chronic Pain Specialty [2014.11.21]
Title: Abuse-Resistant Prescription Painkiller Approved
Category: Health News
Created: 11/20/2014 12:00:00 AM
Last Editorial Review: 11/21/2014 12:00:00 AM

MRI Can Be Painful, Disruptive for People With Cochlear Implants
Source: MedicineNet Deafness Specialty [2014.11.21]
Title: MRI Can Be Painful, Disruptive for People With Cochlear Implants
Category: Health News
Created: 11/20/2014 12:00:00 AM
Last Editorial Review: 11/21/2014 12:00:00 AM

Infants experience less pain in mother's soothing presence and gene activity in infant brain altered
Source: Neurology / Neuroscience News From Medical News Today [2014.11.20]
Research led by NYU Langone Medical Center offers insight into short-term effects of maternal caregiving on a developing brainA mother's "TLC" not only can help soothe pain in infants, but it may...

Inflammation Triggers Pain of Knee OA
Source: MedPage Today Surgery [2014.11.20]
(MedPage Today) -- New analysis points to new target to ease pain.

more news >>

Published Studies Related to Acular PF (Ketorolac Tromethamine Ophthalmic)

Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. [2011]
BACKGROUND/AIMS: To evaluate the benefit of adding a nonsteroid agent to an antibiotic/steroid combination after uneventful phacoemulsification, adopting a weekly follow-up, to gain insight into the optimal duration of postoperative treatment and to examine whether risk factors for inflammation exist... CONCLUSION: The addition of ketorolac did not seem to offer any additional benefit in terms of inflammation-related signs. Four weeks appeared as an adequate treatment interval. Special attention should be paid to patients with pseudoexfoliation. Copyright (c) 2010 S. Karger AG, Basel.

Penetration of topically applied diclofenac and ketorolac into the aqueous humour and subretinal fluid: randomized clinical trial. [2010.12]
OBJECTIVE: To determine the level of intraocular penetration of diclofenac sodium and ketorolac tromethamine into the aqueous humour and subretinal fluid. DESIGN: Prospective randomized clinical trial. PARTICIPANTS: Twenty eyes scheduled for retinal detachment surgery and 17 eyes scheduled for cataract surgery... CONCLUSIONS: The concentration in the subretinal fluid of topically applied diclofenac was higher than that of ketorolac; and topical ketorolac penetrated into the aqueous humour better than diclofenac did. This suggests that diclofenac can be used more effectively in events related to posterior segment and ketorolac in anterior segment events.

Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. [2010.05]
PURPOSE: To compare the anti-inflammatory efficacy and subjective tolerability of preservative-free and preserved diclofenac 0.1% and preserved ketorolac 0.5% eye drops for prophylaxis and management of inflammation after cataract surgery. DESIGN: Prospective, randomized, investigator-masked, parallel-group, comparative clinical trial... CONCLUSIONS: Anti-inflammatory efficacy was comparable for all 3 agents. However, preservative-free diclofenac 0.1% eyedrops exhibited a significantly better postoperative subjective and objective tolerability when compared with preserved eyedrops containing ketorolac or diclofenac. Copyright 2010 Elsevier Inc. All rights reserved.

Use of Acular LS in the pain management of keratoconus: a pilot study. [2010.02]
PURPOSE: The purpose of this pilot study was to determine the efficacy of ketorolac tromethamine 0.4% for pain management in conjunction with rigid gas permeable contact lenses in keratoconus. Any potential side effects and complications of this application were examined... CONCLUSIONS: There was no conclusive result as to the efficacy of the ketorolac tromethamine 0.4% vs. the artificial tear solution in the pain management of keratoconus. This could be attributed to a number of physiological and situational factors, as well as small sample size.

Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. [2009.06]
INTRODUCTION: Ketorolac 0.4% administered four times daily (q.i.d.) has long been used safely and effectively for the alleviation of ocular inflamation and pain and the prevention of intraoperative miosis in patients undergoing cataract surgery. Bromfenac ophthalmic solution 0.09% was recently developed as an ocular anti-inflammatory drug with a twice-daily (b.i.d.) dosing regimen. This study was designed to evaluate if b.i.d. dosing with bromfenac 0.09%, in comparison with q.i.d. dosing with ketorolac 0.4%, provides adequate trough nonsteroidal anti-inflammatory drug levels that were effective enough to reduce aqueous prostaglandin (PG) E(2) levels of patients after cataract surgery toward the end of its dosing cycle... CONCLUSIONS: Ketorolac 0.4% maintained significantly higher aqueous concentrations and lowered aqueous PGE(2) levels significantly more than bromfenac 0.09% at trough levels. Ketorolac 0.4% administered q.i.d. may provide a more sustained control of intraocular inflammation and pain than bromfenac 0.09% administered b.i.d.

more studies >>

Clinical Trials Related to Acular PF (Ketorolac Tromethamine Ophthalmic)

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity [Enrolling by invitation]
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity. In this study ACULAR will be compared to a placebo (artificial tear).

The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to severe ROP (grade II and above)by 50%.

An Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain [Not yet recruiting]
The purpose of this study is to determine the effectiveness, the safety, and the tolerability of intranasal ketorolac (Sprix) in relieving acute pain in adults ages 18-64 who come to the ED seeking care. Considering all ED visits, pain is the most common chief complaint. Giving intranasal ketorolac (Sprix) after stomach and dental surgeries has been shown to be safe and effective, but no studies have investigated the use of intranasal ketorolac (Sprix) for the treatment of acute pain in the ED.

Ketorolac (Sprix) has several advantages over other drugs commonly given for pain, including opioids. Ketorolac (Sprix) is non-addicting and has fewer side effects than opioids. The administration of ketorolac (Sprix) by other methods, such as IV, intramuscular shot, and oral pill form, has been shown to be safe and effective in treating acute pain.

This study is being done to find out if giving ketorolac (Sprix) as a single dose nasal spray will have the same benefit in decreasing patient's pain.

Disposition of Intravenous Ketorolac [Not yet recruiting]
The purpose of this study is:

- to document ketorolac disposition (concentration/time profile, protein binding,

metabolism) and its covariates following intravenous (iv) administration of ketorolac right after caesarean section and to compare those observations (n=32) with non-pregnant state (n=8) (intra-subject PK comparison)

- to document biochemical tolerance of ketorolac

- to evaluate if optimalisation of ketorolac dose regimen during pregnancy and labor are

appropriated and needed

- to quantify the neonatal exposure to ketorolac through excretion in the breast milk

Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement [Recruiting]
Intrauterine device (IUD) placement can be painful for patients during and after the procedure. Fear of pain from IUD insertion can be a barrier to obtaining this highly effective long acting reversible contraception. Currently there are no proven effective methods for reduction of pain during and after placement of modern IUDs (Mirena IUD and Paragard IUD). Ketorolac has not been studied in regards to decreasing pain during and after IUD insertion although it is used by some providers for this purpose. It is a strong NSAID that is indicated for the treatment of moderate acute pain. In the intramuscular form it has an analgesia onset of action at 30min, thus may be a plausible option for pain management in the office setting compared to oral NSAIDs, which have a longer time to onset of analgesia and have not been proven to be effective in reducing pain associated with IUD placement. The primary aim of this study is to determine whether ketorolac (Toradol) decreases pain associated with intrauterine device placement compared to placebo. We hypothesize that administration of ketorolac 30mg intramuscularly at least 30 minutes prior to IUD insertion will decrease pain scores by at least 20mm on a visual analog scale at various time points during IUD insertion when compared to placebo of normal saline injection.

Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose. [Recruiting]
The primary aim of this study is to show the non-inferiority of 15 mg intraoperative dose of ketorolac as compared to the standard 30 mg ketorolac by looking at the VAS scores 4 hours after an adult spine surgery.

more trials >>


Page last updated: 2014-11-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014